1:39 PM
 | 
May 11, 2018
 |  BioCentury  |  Emerging Company Profile

Enterin the gut

How Enterin’s compound could help treat Parkinson’s disease constipation

Enterin Inc. has a new twist on the longstanding Parkinson’s disease target alpha synuclein. The biotech is inhibiting the protein’s accumulation in intestinal nerves rather than in the brain, with the goal of treating constipation and non-motor symptoms associated with the disease.

Alpha synuclein (SNCA) is a major component of Lewy bodies, a type of protein aggregate that builds up in the brains of PD patients. But the protein is also expressed in the gastrointestinal (GI) tract, and accumulates in intestinal nerves during the disease.

Enterin President and CMO Denise Barbut believes PD-associated constipation results from synuclein aggregates clogging GI nerves and preventing stimulation of the rhythmic muscle contractions that move food along.

The company’s lead candidate kenterin (ENT-01) is a synthetic derivative of squalamine, a compound CEO Michael Zasloff discovered in...

Read the full 643 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >